New markets the big catalyst for MVP

Mark Newman

K2 Asset Management

The United States is currently a key focus for management and will provide the next major catalyst for a re-rating; given the market could be twice that of Europe. With the help of a leading advisory firm, submissions to the FDA are being prepared with MVP in a strong position to receive approval. Should the company establish a signed distribution agreement with a major US pharmaceutical company along with positive news flow surrounding the FDA approval process; the stock is likely to further re-rate to better reflect its growth opportunities.


Mark Newman
Joint Chief Investment Officer
K2 Asset Management

Mark is a Co-Founder and Executive Director of K2 Asset Management. He is also the Joint-CIO for the K2 investment funds and focuses on the portfolio management of the Asian equity strategy.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.